Metabolic & Weight Management
Liraglutide
Also known as Victoza · Saxenda
Clinically studiedSubcutaneous injectionFDA-approved (Victoza for type 2 diabetes; Saxenda for weight management); generic available. Carries a boxed warning for thyroid C-cell tumor risk seen in rodents.
Liraglutide is a daily-injection GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1. It increases glucose-dependent insulin secretion, reduces hepatic glucose output, slows digestion, and acts on appetite-regulation centers to decrease food intake. It is an earlier-generation GLP-1 agent now also available as a generic.
Studied / used for
- studied for glycemic control in type 2 diabetes
- studied for chronic weight management in obesity/overweight
Commonly reported side effects
- nausea
- diarrhea
- vomiting
- constipation
- headache
- decreased appetite
- injection-site reactions
Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.
Not medical advice.
This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.